LifeVantage acquires LoveBiome

LifeVantage (LFVN) has entered into a definitive agreement to acquire LoveBiome, a direct sales company dedicated to comprehensive microbiome care and wellness solutions. LoveBiome’s expertise in microbiome science complements LifeVantage’s existing portfolio of scientifically validated activators. Rationale for the acquisition includes growth of LifeVantage Consultant network in key markets including the US, Taiwan, and Europe; strengthened position in direct sales industry; expanded product portfolio with Activation differentiation in gut and microbiome health. The global gut health supplement market is projected to grow from $14.4B in 2025 to $32.4B by 2035, registering a CAGR of 8.4%. Enhances revenue growth and is expected to be accretive to Adjusted EPS and Adjusted EBITDA in year one with additional synergy opportunity. The transaction structure includes the retention of key LoveBiome personnel, with founder and CEO Kelly Olsen, and other team members joining LifeVantage to ensure continuity of operations and leverage their expertise in the direct sales channel. The acquisition is expected to close by mid-October upon satisfaction of customary closing conditions and regulatory requirements.